1. Ben Salem, C., Slim, R., Fathallah, N. & Hmouda, H. (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford), 56, 679-688.
2. Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J. & Wang, X. (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv, doi:10.1101/2020.03.17.20037432.
3. Du, Y.X. & Chen, X.P. (2020) Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther., doi: 10.1002/cpt.1844. [Epub ahead of print].
4. Fujifilm Toyama Chemical Co., Ltd. (Fujifilm) (2019) The drug interview form of favipiravir (Avigan®) (April. 2019 version). http://fftc.fujifilm.co.jp/med/abigan/pack/pdf/abigan_if_01.pdf [Accessed: May 5, 2015] (in Japanese).
5. Fujita Health University Hospital (2020) Interim report of observational study of favipiravir (May. 26. 2020 version). http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_favip_0526.pdf [Accessed: May 27, 2015] (in Japanese).